Ischaemic and bleeding risk in cancer patients undergoing PCI: another brick in the wall.

[1]  Deepak L. Bhatt,et al.  Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. , 2021, European heart journal.

[2]  N. Lannin,et al.  Factors Associated with Stroke Coding Quality: A Comparison of Registry and Administrative Data. , 2020, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[3]  C. Cipolla,et al.  Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer , 2020, Journal of clinical medicine.

[4]  M. Price,et al.  Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. , 2020, The New England journal of medicine.

[5]  L. Räber,et al.  Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention , 2019, JACC. CardioOncology.

[6]  H. Jneid,et al.  Acute Coronary Syndromes in Cancer Patients. , 2019, European heart journal.

[7]  R. Souza,et al.  Cancer-associated thrombosis: the when, how and why , 2019, European Respiratory Review.

[8]  D. Fischman,et al.  Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. , 2018, European heart journal.

[9]  Takeshi Kimura,et al.  Influence of a history of cancer on long-term cardiovascular outcomes after coronary stent implantation (an Observation from Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2) , 2018, European heart journal. Quality of care & clinical outcomes.

[10]  H. Kamel,et al.  Risk of Arterial Thromboembolism in Patients With Cancer. , 2017, Journal of the American College of Cardiology.

[11]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[12]  C. Criscitiello,et al.  Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management , 2016, CA: a cancer journal for clinicians.

[13]  A. Falanga,et al.  Coagulation and cancer: biological and clinical aspects , 2013, Journal of thrombosis and haemostasis : JTH.

[14]  J. Durand,et al.  Treatment and Outcomes of Acute Coronary Syndrome in the Cancer Population , 2012, Clinical cardiology.

[15]  T. Truelsen,et al.  Validity of Stroke Diagnoses in a National Register of Patients , 2007, Neuroepidemiology.